文献速递糖尿病

飞行中大气压力变化对使用胰岛素治疗的飞行员胰岛素泵输注及血糖控制的影响:体外模拟与回顾性观察性真实世界研究

Effects of atmospheric pressure change during flight on insulin pump delivery and glycaemic control of pilots with insulin-treated diabetes: an in vitro simulation and a retrospective observational real-world study.
PubMed 文献 · Diabetologia · 2024-11-04

研究通过低压舱体外模拟飞行大气压变化测试胰岛素泵输注,并回顾7.5年飞行员真实世界血糖数据。模拟中完整卡式瓶在上升20分钟过输注0.60 U、下降欠输注0.51 U,紧急快速减压多输注5.6 U;真实世界中使用持续皮下胰岛素输注(CSII)的7名飞行员飞行中未出现血糖下降或低血糖,血糖达标比例高于每日多次注射(MDI)组。

要点

  • 模拟飞行中完整卡式瓶上升20分钟过输注0.60 U,下降欠输注0.51 U,紧急快速减压多输注5.6 U。
  • 真实世界使用CSII的7名飞行员飞行中仅0.7%血糖值超出5.0-15.0 mmol/l安全范围,无低血糖值。
  • CSII组血糖达标比例99.3%高于MDI组97.5%,飞行中超标值0.2%低于MDI组1.3%。

核心结论

  • 模拟飞行环境压力降低导致胰岛素卡式瓶内气泡形成和膨胀,引起独立于设定输注速率的小剂量意外输注,代表可能输注和回抽的最大胰岛素量。
  • 真实世界中飞行中使用CSII的飞行员在这些大气压力变化期间未出现血糖下降或低血糖发作,鉴于其临床获益,胰岛素泵的使用可得到支持。

研究设计与样本

  • 飞行模拟部分为低压舱体外研究,将胰岛素泵减压至550 mmHg以模拟商业航班客舱大气压变化,记录标准飞行方案下胰岛素输注速率和气泡形成,并在模拟快速减压场景中测试无泵的胰岛素输注管路。
  • 真实世界部分为7.5年回顾性队列研究,纳入获得欧盟航空安全局批准方案下飞行医学证书、接受胰岛素泵或每日多次注射(MDI)治疗的商业和私人飞行员,监测飞行前和飞行中自我血糖监测(SMBG)值。

主要发现

  • 飞行模拟研究中,完整卡式瓶在20分钟上升期间较地面水平过输注0.60 U胰岛素,下降期间欠输注0.51 U。
  • 紧急快速减压期间多输注5.6 U胰岛素。
  • 真实世界研究中,7名使用CSII的飞行员在1081次飞行、2345飞行小时中记录4656个SMBG值,仅33个(0.7%)超出可接受安全范围(5.0-15.0 mmol/l [90-270 mg/dl])。
  • 飞机上升后中位SMBG浓度未观察到临床显著下降,飞行中无SMBG值位于低血糖范围(<4.0 mmol/l [<72 mg/dl])。
  • 与接受MDI治疗的飞行员相比,使用CSII的飞行员记录到更多在可接受范围内的SMBG值(99.3% vs 97.5%),更少处于低红色范围的值(0.02% vs 0.1%),更少飞行中超出范围的值(0.2% vs 1.3%),并在飞行中维持更严格的血糖控制。

临床怎么用

  • 作者认为,鉴于胰岛素泵的临床获益,飞行中使用CSII可得到支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glycaemic control and clinical outcomes in diabetes are improved by continuous subcutaneous insulin infusion (CSII). Atmospheric pressure changes during flights may affect insulin delivery from pumps and cause unintended metabolic consequences, including hypoglycaemia, in people with type 1 diabetes. The present report evaluates both hypobaric flight simulation and real-world data in pilots using insulin pumps while flying. METHODS: In the flight simulation part of this study, an in vitro study of insulin pumps was conducted in a hypobaric chamber, de-pressurised to 550 mmHg to mimic the atmospheric pressure changes in airliner cabins during commercial flights. Insulin delivery rates and bubble formation were recorded for standard flight protocol. Insulin infusion sets, without pumps, were tested in a simulated rapid decompression scenario. The real-world observational study was a 7.5-year retrospective cohort study in which pre- and in-flight self-monitored blood glucose (SMBG) values were monitored in pilots with insulin-treated diabetes. Commercial and private pilots granted a medical certificate to fly within the European Union Aviation Safety Agency approved protocol and receiving insulin either by pump or multiple daily injections (MDI) were included. RESULTS: In the flight simulation study, full cartridges over-delivered 0.60 U of insulin during a 20 min ascent and under-delivered by 0.51 U during descent compared with ground-level performance. During emergency rapid decompression, 5.6 U of excess insulin was delivered. In the real-world study, seven pilots using CSII recorded 4656 SMBG values during 2345 h of flying across 1081 flights. Only 33 (0.7%) values were outside an acceptable safe range (5.0-15.0 mmol/l [90-270 mg/dl]). No clinically significant fall in the median SMBG concentration was observed after aircraft ascent and no in-flight SMBG values were within the hypoglycaemic range (<4.0 mmol/l [<72 mg/dl]). Compared with pilots receiving MDI therapy, pilots using CSII recorded more SMBG values within the acceptable range (99.3% vs 97.5%), fewer values in the low red range (0.02% vs 0.1%), fewer in-flight out-of-range values (0.2% vs 1.3%) and maintained stricter glycaemic control during flight. CONCLUSIONS/INTERPRETATION: Ambient pressure reduction during simulated flights results in bubble formation and expansion within insulin cartridges. This causes unintended delivery of small insulin doses independent of pre-determined delivery rates and represents the maximum amount of insulin that could be delivered and retracted. However, in vivo, pilots using CSII in-flight did not experience a fall in blood glucose or episodes of hypoglycaemia during these atmospheric pressure changes and the use of insulin pumps can be endorsed in view of their clinical benefits.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Garden GL, Fan KS, Paterson M, et al. Effects of atmospheric pressure change during flight on insulin pump delivery and glycaemic control of pilots with insulin-treated diabetes: an in vitro simulation and a retrospective observational real-world study. Diabetologia. 2024. PMID: 39496965. doi:10.1007/s00125-024-06295-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。